Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world reported adverse events related to systemic immunomodulating therapy in patients with atopic dermatitis: Results from the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.
Musters AH, van Lookeren FL, van der Gang LF, Middelkamp-Hup MA, Bosma AL, Jessurun NT, Lapeere H, Nguyen AL, Ouwerkerk W, de Schepper S, Gerbens LAA, Spuls PI. Musters AH, et al. Among authors: jessurun nt. J Eur Acad Dermatol Venereol. 2024 Mar;38(3):530-542. doi: 10.1111/jdv.19643. Epub 2023 Nov 29. J Eur Acad Dermatol Venereol. 2024. PMID: 38031478
Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals.
van Lint JA, Jessurun NT, Tas SW, van den Bemt BJF, Nurmohamed MT, van Doorn MBA, Spuls PI, van Tubergen AM, Ten Klooster PM, van Puijenbroek EP, Hoentjen F, Vonkeman HE. van Lint JA, et al. Among authors: jessurun nt. J Rheumatol. 2021 Sep;48(9):1388-1394. doi: 10.3899/jrheum.201373. Epub 2021 May 15. J Rheumatol. 2021. PMID: 33993115
Patients' perspectives on a drug safety monitoring system for immune-mediated inflammatory diseases based on patient-reported outcomes.
Kosse LJ, Weits G, Vonkeman HE, Tas SW, Hoentjen F, Van Doorn MB, Spuls PI, D'Haens GR, Nurmohamed MT, van Puijenbroek EP, Van Den Bemt BJ, Jessurun NT. Kosse LJ, et al. Among authors: jessurun nt. Expert Opin Drug Saf. 2021 Dec;20(12):1565-1572. doi: 10.1080/14740338.2021.1963436. Epub 2021 Aug 12. Expert Opin Drug Saf. 2021. PMID: 34348543
Analysis and visualization of the course and burden over time of adverse drug reactions (ADRs) attributed to TNFα-inhibitors in patients with inflammatory rheumatic diseases (IRDs).
de Boer M, Gosselt HR, Jansen J, van Doorn MBA, Hoentjen F, Nurmohamed MT, Spuls PI, Tas SW, Vonkeman HE, Jessurun NT. de Boer M, et al. Among authors: jessurun nt. Expert Opin Drug Saf. 2023 Mar;22(3):195-202. doi: 10.1080/14740338.2022.2110237. Epub 2022 Aug 10. Expert Opin Drug Saf. 2023. PMID: 35946722
Barriers and facilitators for systematically registering adverse drug reactions in electronic health records: a qualitative study with Dutch healthcare professionals.
Geeven IPAC, Jessurun NT, Wasylewicz ATM, Drent M, Spuls PI, Hoentjen F, van Puijenbroek EP, Vonkeman HE, Grootens KP, van Doorn MBA, van Den Bemt BJF, Bekker CL. Geeven IPAC, et al. Among authors: jessurun nt. Expert Opin Drug Saf. 2022 May;21(5):699-706. doi: 10.1080/14740338.2022.2020756. Epub 2022 Jan 24. Expert Opin Drug Saf. 2022. PMID: 35060443 Free article.
51 results